10-K · February 18, 2026
Insulet reported strong 2025 operating performance with total revenue up 30.7% to $2,708.1 million driven by Omnipod product volume and international rollouts; gross margin expanded to 71.6% and free cash flow rose to…
Earnings analysis · 10-Q
PODD earnings analysis
Filed May 6, 2026 · Our reading of the company's report
The latest report
Insulet Corporation's Q1 2026 results showcased strong growth, with revenue of $761.7 million and an EPS of $1.42, exceeding estimates and reflecting a 33.9% increase from the prior year. The growth was driven primarily…
Read full summary
Insulet Corporation's Q1 2026 results showcased strong growth, with revenue of $761.7 million and an EPS of $1.42, exceeding estimates and reflecting a 33.9% increase from the prior year. The growth was driven primarily by robust sales of Omnipod products in both the U.S. (up 28.3%) and international markets (up 59.4%). The company continues to expand its Omnipod 5 product in new markets while navigating increased costs and a decline in gross margin.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $1.42
- Gross margin
- 69.5%
- Segment
- U.S. Omnipod: $515.6M; International Omnipod: $242.9M; Drug Delivery: $3.3M
What stood out
-
Significant Revenue Growth
Revenue grew by 33.9% year-over-year to $761.7 million from $569.0 million.
-
Strong EPS Beat
Reported EPS of $1.42 surpassed estimates of $1.18.
-
U.S. Omnipod Sales Surge
U.S. revenue from Omnipod products rose by 28.3% to $515.6 million.
-
International Sales High
International revenue increased by 59.4% to $242.9 million.
-
Improved Free Cash Flow
Free cash flow increased to $89.5 million from $51.6 million year-over-year.
-
Raising Full-Year Guidance
Management anticipates 21%-23% growth in total revenue for the full year.
What to watch
-
Declining Gross Margin
Gross margin decreased from 71.9% to 69.5%, impacted by inventory reserves and warranty costs.
-
Increased Debt Levels
Debt-to-total capital ratio increased to 42% from 39%.
-
Regulatory Costs
Estimated costs related to a voluntary medical device correction are around $30 million, affecting margins.
Management's outlook
Management raised full-year revenue guidance to reflect stronger demand and growth expectations.
Earlier filings 4
10-Q · May 9, 2025
Insulet reported Q1 revenue of $569.0M, up $127.3M (+28.8%) year-over-year, with gross profit of $409.0M (71.9% gross margin) and operating income of $88.8M (15.6% operating margin). GAAP diluted EPS was $0.50 and net…
10-Q · November 8, 2024
Insulet reported a strong Q3: total revenue of $543.9M (up $111.2M or 25.7% vs Q3 2023) and diluted EPS of $1.08 (vs $0.74). Gross profit was $377.1M (gross margin ~69.3%) and operating income was $88.1M (operating…
10-Q · August 9, 2024
Insulet reported a strong quarter of operational growth: Q2 revenue was $488.5 million (up $92.0 million vs. Q2 2023) with improved operating margin of 11.2% and gross profit of $330.9 million. Net income of $188.6…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.